MRK Merck & Co Inc

Price (delayed)

$92.42

Market cap

$233.71B

P/E Ratio

16.47

Dividend/share

$2.72

EPS

$5.61

Enterprise value

$256.95B

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the ...

Highlights
The EPS has soared by 102% YoY and by 9% from the previous quarter
The net income has surged by 102% year-on-year and by 9% since the previous quarter

Key stats

What are the main financial stats of MRK
Market
Shares outstanding
2.53B
Market cap
$233.71B
Enterprise value
$256.95B
Valuations
Price to earnings (P/E)
16.47
Price to book (P/B)
5.71
Price to sales (P/S)
4.33
EV/EBIT
16.04
EV/EBITDA
13.23
EV/Sales
4.76
Earnings
Revenue
$53.98B
EBIT
$16.02B
EBITDA
$19.42B
Free cash flow
$12.78B
Per share
EPS
$5.61
Free cash flow per share
$5.06
Book value per share
$16.17
Revenue per share
$21.35
TBVPS
$24.68
Balance sheet
Total assets
$106.67B
Total liabilities
$65.72B
Debt
$31.79B
Equity
$40.88B
Working capital
$8.87B
Liquidity
Debt to equity
0.78
Current ratio
1.4
Quick ratio
0.84
Net debt/EBITDA
1.2
Margins
EBITDA margin
36%
Gross margin
70.7%
Net margin
26.3%
Operating margin
28.9%
Efficiency
Return on assets
14.3%
Return on equity
38.3%
Return on invested capital
27.4%
Return on capital employed
19%
Return on sales
29.7%
Dividend
Dividend yield
2.94%
DPS
$2.72
Payout ratio
48.5%

MRK stock price

How has the Merck stock price performed over time
Intraday
1.37%
1 week
-0.76%
1 month
1.4%
1 year
18.5%
YTD
20.59%
QTD
1.37%

Financial performance

How have Merck's revenue and profit performed over time
Revenue
$53.98B
Gross profit
$38.17B
Operating income
$15.57B
Net income
$14.18B
Gross margin
70.7%
Net margin
26.3%
Merck's operating margin has surged by 170% YoY and by 12% QoQ
The net income has surged by 102% year-on-year and by 9% since the previous quarter
MRK's net margin has surged by 57% year-on-year
The gross profit has grown by 37% year-on-year and by 9% since the previous quarter

Growth

What is Merck's growth rate over time

Valuation

What is Merck stock price valuation
P/E
16.47
P/B
5.71
P/S
4.33
EV/EBIT
16.04
EV/EBITDA
13.23
EV/Sales
4.76
The EPS has soared by 102% YoY and by 9% from the previous quarter
The P/E is 57% lower than the 5-year quarterly average of 38.3 and 28% lower than the last 4 quarters average of 22.8
Merck's equity has soared by 52% YoY and by 7% from the previous quarter
The price to book (P/B) is 12% lower than the 5-year quarterly average of 6.5 but 8% higher than the last 4 quarters average of 5.3
The revenue has grown by 29% YoY and by 11% from the previous quarter
MRK's P/S is 6% below its 5-year quarterly average of 4.6 but 6% above its last 4 quarters average of 4.1

Efficiency

How efficient is Merck business performance
The company's return on assets has surged by 86% YoY and by 4.4% QoQ
The ROIC has soared by 81% YoY and by 6% QoQ
The ROS has soared by 53% YoY
Merck's ROE has increased by 48% YoY

Dividends

What is MRK's dividend history
DPS
$2.72
Dividend yield
2.94%
Payout ratio
48.5%
Recent dividends

Financial health

How did Merck financials performed over time
The total assets is 62% more than the total liabilities
MRK's quick ratio is up by 45% year-on-year and by 15% since the previous quarter
The current ratio has grown by 37% YoY and by 10% from the previous quarter
MRK's debt is 22% smaller than its equity
Merck's equity has soared by 52% YoY and by 7% from the previous quarter
The debt to equity has contracted by 33% YoY and by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.